Research & Development
PENAO-01 clinical trial completed
26 patients with advanced solid tumours enrolled at three Australian hospitals.
Patient with anaplastic astrocytoma had stable disease at 6 mg/m2/day over 10 cycles (30 weeks).
Eight dose levels investigated. Maximum Tolerated Dose not reached.
R&D Pipeline
- A Phase II clinical trial is planned to investigate combination therapies and doses in ~50 patients with Breast Cancer or Non-Small Cell Lung Cancer (NSCLC) at hospitals across Australia and China.
- Nonclinical studies contracted in Australia will add value and potentially accelerate the approval process.
- Development and optimisation of manufacturing operations.